Response to MHRA’s consultation on the availability of diclofenac as a pharmacy medicine

MHRA (Medicines and Healthcare Products Regulatory Agency) ran a consultation on the continued availability of diclofenac as a Pharmacy (P) medicine and on the risk minimisation measures advised by the Commission on Human Medicines.

The Society recommended that diclofenac tablets be reclassified to a prescription only medicine.

• Read more on the Society's response to the consultation here.